

Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/P11BD894351EN.html>

Date: July 2021

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: P11BD894351EN

Abstracts

Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharma Mar SA (Pharma Mar) discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. Pharma Mar also offers kits used for diagnosis of SARS-CoV-2, influenza A and B and respiratory syncytial virus. Its development pipeline includes PM184 and PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK and the US, among others. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA Key Recent Developments

May 05,2021: PharmaMar Group reports first quarter 2021 earnings as of March 31st , 2021

May 05,2021: PharmaMar Group reports first quarter 2021 earnings as of March 31st ,

2021

Feb 26,2021: PharmaMar Group reports record results for 2020

Feb 11,2021: PharmaMar enlarges its facilities to meet its upcoming business challenges

Nov 03,2020: PharmaMar Group presents results up to September 30th 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Pharma Mar SA - Key Facts
Pharma Mar SA - Key Employees
Pharma Mar SA - Key Employee Biographies
Pharma Mar SA - Major Products and Services
Pharma Mar SA - History
Pharma Mar SA - Company Statement
Pharma Mar SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Pharma Mar SA - Business Description
Business Segment: Diagnostic
Overview
Performance
Business Segment: Oncology
Overview
Performance
Business Segment: RNAi
Overview
Performance
Business Segment: Unallocated
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Rest of the European Union
Performance

Geographical Segment: Spain
Performance
Geographical Segment: The US
Performance
R&D Overview
Pharma Mar SA - Corporate Strategy
Pharma Mar SA - SWOT Analysis
SWOT Analysis - Overview
Pharma Mar SA - Strengths
Pharma Mar SA - Weaknesses
Pharma Mar SA - Opportunities
Pharma Mar SA - Threats
Pharma Mar SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Pharma Mar SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 05, 2021: PharmaMar Group reports first quarter 2021 earnings as of March 31st , 2021
May 05, 2021: PharmaMar Group reports first quarter 2021 earnings as of March 31st , 2021
Feb 26, 2021: PharmaMar Group reports record results for 2020
Feb 11, 2021: PharmaMar enlarges its facilities to meet its upcoming business challenges
Nov 03, 2020: PharmaMar Group presents results up to September 30th 2020

Jul 30, 2020: PharmaMar Group reported net profit of €113.8M at June 30th , 2020

Apr 23, 2020: PharmaMar presents results for the first quarter 2020

Feb 26, 2020: PharmaMar presents results for 2019

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Pharma Mar SA, Key Facts
Pharma Mar SA, Key Employees
Pharma Mar SA, Key Employee Biographies
Pharma Mar SA, Major Products and Services
Pharma Mar SA, History
Pharma Mar SA, Subsidiaries
Pharma Mar SA, Key Competitors
Pharma Mar SA, Ratios based on current share price
Pharma Mar SA, Annual Ratios
Pharma Mar SA, Annual Ratios (Cont...1)
Pharma Mar SA, Annual Ratios (Cont...2)
Pharma Mar SA, Interim Ratios
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Pharma Mar SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Pharma Mar SA, Performance Chart (2016 - 2020)

Pharma Mar SA, Ratio Charts

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/P11BD894351EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P11BD894351EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970